Compare Inovio Pharmaceuticals Inc (INO) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while IQIYI Inc - ADR trades at $1.24 (market cap $1.20B). The key difference: IQIYI Inc - ADR is far larger — about 13.4× Inovio Pharmaceuticals Inc's market cap, and IQIYI Inc - ADR is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | IQ | |
|---|---|---|
Market Cap | $89.27M | $1.20B |
Sector | Health | Media |
52-Week High | $2.87 | $2.79 |
52-Week Low | $1.05 | $0.96 |
Enterprise Value | $60.28M | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
IQ stock trades at $1.235, up 3.78% today, with a bullish technical signal and mixed fundamentals. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, but valuation ratios like P/S of 0.3 and P/B of 0.6 appear low. Recent news highlights AI initiatives and leadership changes, while analyst consensus is split with 50% buy ratings.
The outlook is cautious due to profitability challenges and projected revenue decline in 2026, but low valuations and AI-driven content strategy offer potential upside. Key risks include competitive pressures in streaming and regulatory uncertainty in China.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
